Pictet Asset Management
SLNO

Pictet Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Pictet Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-616,217
Closed -$20.6M – 2196
2026
Q1 		$20.6M Sell
616,217
-7,911
-1% -$310K 0.02% 492
2025
Q4 		$28.9M Buy
624,128
+73,504
+13% +$4.03M 0.03% 433
2025
Q3 		$37.2M Sell
550,624
-101,428
-16% -$7.52M 0.04% 378
2025
Q2 		$54.6M Sell
652,052
-185,784
-22% -$13.9M 0.06% 305
2025
Q1 		$59.9M Sell
837,836
-14,002
-2% -$682K 0.07% 280
2024
Q4 		$38.3M Buy
851,838
+276,225
+48% +$14.3M 0.04% 353
2024
Q3 		$29.1M Buy
575,613
+143,853
+33% +$6.89M 0.03% 396
2024
Q2 		$17.6M Buy
431,760
+97,908
+29% +$4.15M 0.02% 498
2024
Q1 		$14.3M Buy
+333,852
New +$15.1M 0.02% 576

Pictet Asset Management's SLNO Position: Q2 2026 in Review

Pictet Asset Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 616,217 shares — an estimated $20.6M sold.

Pictet Asset Management first reported a position in SLNO in Q1 2024 and held it in 9 quarters. The position peaked at $59.9M in Q1 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Pictet Asset Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Pictet Asset Management sold 616,217 Soleno Therapeutics shares in Q2 2026, an estimated $20.6M.
  • Pictet Asset Management first reported a position in Soleno Therapeutics in Q1 2024 and held it in 9 quarters.
  • Pictet Asset Management's Soleno Therapeutics position peaked at $59.9M in Q1 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.